• Imadeldin Elfaki Department of Biochemistry, Faculty of Science, University of Tabuk, Kingdom of Saudi Arabia.
  • Fahad M Almutairi Department of Biochemistry, Faculty of Science, University of Tabuk, Kingdom of Saudi Arabia.
  • Rashid Mir Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk, Kingdom of Saudi Arabia.
  • Roaid Khan Department of Endocrinology, King Salman Armed Forces Hospital, Tabuk, Kingdom of Saudi Arabia
  • Faisel Abu-duhier Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk, Kingdom of Saudi Arabia.


Objective: Cytochrome P450 1B1 (CYP1B1) is involved in the activation of procarcinogens and steroid metabolism. Genetic variants of CYP1B1are associated with altered catalytic activity and disease phenotypes. The purpose of this study was to investigate the role of CYP1B1 (rs1056827) polymorphism in inducing T2D.

Methods: This cross-sectional study enrolled 113 subjects of T2D and 120 controls. DNA was isolated from blood. Genotyping of the rs1056827 wasdone by allele-specific polymerase chain reaction. The frequency of alleles and genotype distribution was compared in T2D cases and healthy controls.Statistical analysis was performed with SPSS, Chi-square, and Fisher exact test. Hardy-Weinberg equilibrium was tested by a χ2 test. The associations between rs1056827 variant genotypes and T2D were estimated by computing the odds ratios and their 95% confidence intervals (CI) from univariate and multivariate logistic regression analysis.

Results: A significant association of rs1056827 was found between T2D cases and controls (p<0.0001). When GG genotype was compared with GT genotype a significant association was found with odd ration (OD)0.24 (95% CI: (0.131–0.452) and risk ratio (RR) 0.45 (0.30–0.67) times the risk of T2D heterozygous with the G/T allele (p≤0.0002). In a comparison of GG homozygous with the TT homozygous, there was no significant association with the OD 0.38 (95% CI: (0.02–6.51) RR 0.55(0.13–2.35), p<0.49. When G allele was compared with the T allele a highly significant association with OD 0.54 (95% [CI]: (0.37–0.80) RR 0.75(0.630–0.897) < p≤0.003 suggesting a possible dominant effect of this polymorphism on T2D risk.

Conclusion: This result suggests a significant association between rs1056827G>T polymorphism and T2D. This finding is limited due to the smaller sample size and can be validated by large sample size studies.

Keywords: CYP1B1rs1056827G>T, Type 2 diabetes (T2D), Single nucleotide polymorphisms, Cytochrome P450, CYP1B1 allelic variants, Allelespecific polymerase chain reaction.


1. Knockaert L, Fromenty B, Robin MA. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: Physiopathological role in liver injury and obesity. FEBS J 2011;278:4252-60.
2. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103-41.
3. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004;14:1-18.
4. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
5. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73.
6. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89- 295.
7. Wang A, Savas U, Stout CD, Johnson EF. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem 2011;286:5736-43.
8. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J, Evisalmi S, Anttila S, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 1997;18:391-7.
9. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008;9:129-43.
10. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004;64:3119-25.
11. Smerdová L, Šmerdová J, Kabátková M, Kohoutek J, Blažek D, Machala M, et al. Upregulation of CYP1B1 expression by inflammatory cytokines is mediated by the p38 MAP kinase signal transduction pathway. Carcinogenesis 2014;35:2534-43.
12. Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008;21:93-101.
13. Badeeb OM, Micheal S, Koenekoop RK, den Hollander AI, Hedrawi MT. CYP1B1 mutations in patients with primary congenital glaucoma from Saudi Arabia. BMC Med Genet 2014;15:109.
14. Zhu ZY, Mu YQ, Fu XM, Li SM, Zhao FX. Association of CYP1B1 gene polymorphisms and the positive expression of estrogen alpha and estrogen beta with endometrial cancer risk. Eur J Gynaecol Oncol 2011;32:188-91.
15. Yu PJ, Chen WG, Feng QL, Chen W, Jiang MJ, Li ZQ. Association between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancer. Med Sci Monit 2015;21:239-45.
16. Hoyo-Vadillo C, Garcia-Mena J, Valladares A, Venturelli CR, Wacher- Rodarte N, Kumate J, et al. Association of CYP2C19 genotype with Type 2 diabetes. Health 2010;2:1184-90.
17. Mahdi F, Raza ST, Rizvi S, Abbas S, Karoli R. Distribution of genetic polymorphisms in drug metabolizing gene cytochrome P450 (CYP2C8*3 and CYP2C9*2) in a North Indian Type 2 diabetes population. Exploratory Res Hypothesis Med 2016;1:42-6.
18. Yamada Y, Matsuo H, Watanabe S, Kato K, Yajima K, Hibino T, et al. Association of a polymorphism of CYP3A4 with Type 2 diabetes mellitus. Int J Mol Med 2007;20:703-7.
19. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004;25:1603-10.
20. Bahijri SM, Jambi HA, Al Raddadi RM, Ferns G, Tuomilehto J. The prevalence of diabetes and prediabetes in the adult population of Jeddah, Saudi Arabia-a community-based survey. PLoS One 2016;11:e0152559. 21. Prabhakar PK. Pathophysiology of secondary complications of diabetes millitus. Asian J Pharm Clin Res 2016;9:32-6.
22. Alhowaish AK. Economic costs of diabetes in Saudi Arabia. J Family Community Med 2013;20:1-7.
23. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with Type 2 diabetes and diabetic vascular complications. Rev Diabetes Stud 2012;9:6-22.
24. Andayani TM, Ibrahim MI, Asdie AH. The association of diabetes related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2:139-45.
25. Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett 2012;324:13-30.
26. Ahmed S, Valen E, Sandelin A, Matthews J. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol Sci 2009;111:254-66.
27. Cho YC, Zheng W, Yamamoto M, Liu X, Hanlon PR, Jefcoate CR. Differentiation of pluripotent C3H10T1/2 cells rapidly elevates CYP1B1 through a novel process that overcomes a loss of Ah Receptor. Arch Biochem Biophys 2005;439:139-53.
28. Liu X, Huang T, Li L, Tang Y, Tian Y, Wang S, et al. CYP1B1 deficiency ameliorates obesity and glucose intolerance induced by high fat diet in adult C57BL/6J mice. Am J Transl Res 2015;7:761-71.
29. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A 2005;102:6207-12.
30. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4.
31. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. New York: WH Freeman; 2002.
32. Palenski TL, Gurel Z, Sorenson CM, Hankenson KD, Sheibani N. Cyp1B1 expression promotes angiogenesis by suppressing NF-?B activity. Am J Physiol Cell Physiol 2013;305:C1170-84.
33. Larsen MC, Bushkofsky JR, Gorman T, Adhami V, Mukhtar H, Wang S, et al. Cytochrome P450 1B1: An unexpected modulator of liver fatty acid homeostasis. Arch Biochem Biophys 2015;571:21-39.
34. Chang I, Fukuhara S, Wong DK, Gill A, Mitsui Y, Majid S, et al. Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men. Tumour Biol 2014;35:10223-30.
35. Kachakova D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, et al. Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients. Turk J Med Sci 2016;46:626-40.
36. Shen Y, Xu Q, Ren M, Cai Y, Xu J. Role of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leiomyoma in Han Chinese: A case-control study. J Obstet Gynaecol Res 2014;40:1077-84.
37. Trubicka J, Grabowska-Klujszo E, Suchy J, Masojc B, Serrano-Fernandez P, Kurzawski G, et al. Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer 2010;10:420.
38. Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med 2011;31:19-23.
39. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, et al. Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 2008;19:1311-21.
40. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-94.
41. Afzali FM, Fard ZT, Akbari ME. The effect of polymorphisms on the Ala 119 ser gene cytochrome P450 1B1*2 on the susceptibility of Iranian women to develop breast cancer. Int J Cancer Manage 2017;10:e4042.
444 Views | 351 Downloads
How to Cite
Elfaki, I., F. M. Almutairi, R. Mir, R. Khan, and F. Abu-duhier. “CYTOCHROME P450 CYP1B1*2 GENE AND ITS ASSOCIATION WITH T2D IN TABUK POPULATION, NORTHWESTERN REGION OF SAUDI ARABIA”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 1, Jan. 2018, pp. 55-59, doi:10.22159/ajpcr.2018.v11i1.21657.
Original Article(s)